• Chrysea Labs and nuBioAge announce an exclusive U.S. supply and distribution agreement for Sprevive® spermidine complex, to be commercialized under nuBioAge’s brand across healthcare practitioner and pharmacy channels; non-exclusive rights are granted to other direct-to-consumer channels.
• The partnership targets the fast-growing healthy longevity market, bringing cutting-edge spermidine science into clinical settings where practitioners can integrate it into long-term healthy ageing strategies.
• The timing is deliberate, Chrysea is simultaneously conducting a study with Mount Sinai’s leading researchers – XPRIZE Healthspan award winners – to better understand how Sprevive® supports immune and metabolic function as part of healthy ageing. The science and the market are moving together.

Cantanhede, Portugal, West Palm Beach, Florida USA and Dublin, Ireland;  30 April 2026

Chrysea Labs, Lda a fully owned subsidiary of Chrysea Limited, Ireland (“Chrysea”) and nuBioAge, LLC (“nuBioAge”) today announced that they have entered into an exclusive supply and distribution agreement for Chrysea’s Sprevive® spermidine complex in the United States, marking a new strategic partnership in the longevity biotech market.

Under the agreement, nuBioAge will exclusively commercialize the product under its SpermaPure™ brand, powered by Sprevive®, across the healthcare practitioner, pharmacy channels, and obtains non-exclusive rights to commercialize through direct-to-consumer channels in the US.  Chrysea retains commercialization rights for direct-to-consumer channels.

As part of the collaboration, Chrysea grants nuBioAge a license to use Chrysea’s technology and brand solely for the commercialization of the product in the US under the SpermaPure™ brand, while retaining full ownership of all underlying intellectual property and scientific data. nuBioAge will be responsible for marketing, distribution, and sales in the US.

“By partnering with nuBioAge in the healthcare practitioner channel, we are ensuring that Sprevive®’s spermidine science is delivered within a clinical framework, where physicians and other qualified practitioners can integrate it thoughtfully into individual care decisions and long-term healthy ageing strategies.” Said Pedro de Noronha Pissarra, CEO of Chrysea.

“At nuBioAge, our mission is to bridge the gap between longevity science and clinical application by providing medical practitioners with the most advanced, science-driven tools available”, said Franck Kacou, co-founder of nuBioAge. Partnering with Chrysea Labs to launch SpermaPure™, powered by Sprevive®, is a significant milestone in that mission.

By introducing the first clinically tested, high-purity, GRAS-recognized spermidine to the U.S. market, we are equipping clinicians with a science-backed solution to support cellular repair as part of healthy aging strategies. We are proud to offer a product that meets the highest standards of purity and clinical rigor, ensuring that both practitioners and patients can trust the biological benefits of their longevity interventions

About Chrysea

Chrysea is a biotechnology company revolutionizing the healthcare and wellness industry with precision healthy-lifespan interventions. Leveraging tools of Synthetic Biology and Data Analytics we have unlocked the potential to manufacture products of unparalleled purity at scale, introducing solutions previously inaccessible to industry. Our approach integrates these advanced tools seamlessly into our operations, enabling us to establish a vertically integrate, sustainable business model that spans from laboratory research, directly to the consumer. Chrysea’s products are backed by rigorous science-backed clinical research, ensuring pure, safe, functional brands that consumers can trust.

For more information visit www.chrysealabs.com or email info@chrysealabs.com

About nuBioAge

nuBioAge is a longevity science and wellness education network serving medical practitioners and allied health professionals focused on delivering patient-centric, evidence-based longevity medicine. With its comprehensive ecosystem of resources, nuBioAge empowers practitioners to leverage advanced pharmacy networks, state-of-the-art assessments and data, and leading longevity research, education, and clinical implementation.

Physician-focused, science-backed, and dedicated to advancing transparent practices, nuBioAge is the go-to hub for practitioners committed to delivering clinical longevity medicine for improved healthspan and lifespan outcomes.

For more information on how nuBioAge is redefining the future of longevity science, visit www.nubioage.com

About Sprevive®

Sprevive® is the first pure spermidine product produced by sustainable fermentation processes. Sprevive® is the first clinically tested pure spermidine product, with a preclinical regulatory safety package for a full dose use of 20 mg/day. Sprevive® is low-volume, water soluble, allergen-free, gluten-free, protein-free, taste-neutral, and free from contaminants — setting a new gold standard in bioactive supplementation.

Through continuous clinical research activities, Chrysea is constantly reaffirming its commitment to advancing longevity biotechnology through scientific rigor, clinical discipline, and translational research. By grounding product development in human biology, dose-response evidence, and well-designed clinical studies, Chrysea aims to help bridge the gap between longevity science and clinical reality while supporting the development of truly first-in-class interventions in the field.

About SpermaPure™

SpermaPure™, powered by Sprevive®, is a premier longevity supplement exclusively commercialized in the United States by nuBioAge through healthcare practitioner and pharmacy channels. Each capsule provides a 20mg dose of high-purity Spermidine (Trihydrochloride), specifically formulated to support autophagy—the body’s essential “quality control” process for cellular renewal and repair.

As the first naturally produced, full-dose spermidine formulation with Generally Regarded as Safe (GRAS) recognition in the U.S., SpermaPure™ sets a new gold standard for bioactive supplementation. 

About Spermidine and Autophagy

Spermidine is a natural component of our normal diet, with average normal diet intakes reported to be from 4.8 to 17 mg/day. Extensive pre-clinical model and cell studies have demonstrated biological benefits from supplementation with spermidine, particularly in cardiovascular function but also immune, gastrointestinal function, the microbiome, and metabolic function.  In the past, clinical studies have been hampered by the lack of a pure spermidine product approved for human use and in a form that enables full dosing.

Spermidine is a mediator of the natural cellular process called autophagy. In 2016, the Nobel Prize in Physiology and Medicine was awarded to Yoshinori Ohsumi for his discoveries of the mechanisms of autophagy and confirming its highly conserved role in maintaining normal cellular function.  Autophagy is described as the quality control and cellular recycling system present in all cells. It removes damaged or dysfunctional intracellular components using well documented processes and is considered a key process in managing cellular stress and maintaining healthy cellular and organ function.  Autophagic processes diminish as the human body ages and that is considered an important factor in healthy aging and longevity. The positive bio-effects of spermidine on aging and human health are considered to be due to its action as a natural inducer of autophagy, thus maintaining the body’s healthy aging capacity and healthspan. For more information on autophagy: Autophagy: Definition, Process, Fasting & Signs

For media enquiries, please contact:

Chrysea Labs, Lda.
Email: pnp@chrysealabs.com​

nuBioAge, LLC
Email: franck@nubioage.com​